One
of the most significant reasons hindering the clinical translation
of nanomedicines is the rapid clearance of intravenously injected
nanoparticles by the mononuclear phagocyte system, particularly by
Kupffer cells in the liver, leading to an inefficient delivery of
nanomedicines for tumor treatment. The threshold theory suggests that
the liver’s capacity to clear nanoparticles is limited, and
a single high dose of nanoparticles can reduce the hepatic clearance
efficiency, allowing more nanomedicines to reach tumor tissues and
enhance therapeutic efficacy. Building upon this theory, researchers
have conducted numerous validation studies based on the same nanoparticle
carrier systems. These studies involve the use of albumin nanoparticles
to improve the therapeutic efficacy of albumin nanomedicines as well
as polyethylene glycol (PEG)-modified liposomal nanoparticles to enhance
the efficacy of PEGylated liposomal nanomedicines. However, there
is no research indicating the feasibility of the threshold theory
when blank nanoparticles and nanomedicine belong to different nanoparticle
carrier systems currently. In this study, we prepared two different
sizes of albumin nanoparticles by using bovine serum albumin. We used
the marketed nanomedicine liposomal doxorubicin hydrochloride injection
(trade name: LIBOD, manufacturer: Shanghai Fudan-zhangjiang Biopharmaceutical
Co., Ltd.), as the representative nanomedicine. Through in vivo experiments,
we found that using threshold doses of albumin nanoparticles still
can reduce the clearance rate of LIBOD, prolong its time in vivo,
increase the area under the plasma concentration–time curve
(AUC), and also lead to an increased accumulation of the drug at the
tumor site. Furthermore, evaluation of in vivo efficacy and safety
further indicates that threshold doses of 100 nm albumin nanoparticles
can enhance the antitumor effect of LIBOD without causing harm to
the animals. During the study, we found that the particle size of
albumin nanoparticles influenced the in vivo distribution of the nanomedicine
at the same threshold dose. Compared with 200 nm albumin nanoparticles,
100 nm albumin nanoparticles more effectively reduce the clearance
efficiency of LIBOD and enhance nanomedicine accumulation at the tumor
site, warranting further investigation. This study utilized albumin
nanoparticles to reduce hepatic clearance efficiency and enhance the
delivery efficiency of nonalbumin nanocarrier liposomal nanomedicine,
providing a new avenue to improve the efficacy and clinical translation
of nanomedicines with different carrier systems.